News

New cancer collaborations
Enlarge image

BusinessFranceSwitzerland

New cancer collaborations

30.01.2013 - Swiss 4-Antibody and Ludwig Institute will expand their cooperation, while Curie-Cancer and Genosplice Technology inked a cancer genomics pact.

The two new cancer collaborations were kicked-off yesterday. The French bioinformatics expert Genosplice Technology and the tech-transfer arm of Paris-based Institut Curie aim at developing high value-added cancer genomic approaches. GenoSplice will gain access to several Curie-Cancer technology platforms and research programmes and will contribute to the development of new products against cancer through genome mapping using its bioinformatics expertise. The partners aim to define a genomic map for prostate cancer including pathways and therapeutic options. In a second project the French will seek response biomarkers for a preclinical peptide that already has been proven effective in mouse xenograft experiments. 

On the same day, Swiss 4-Antibody AG and US-based Ludwig Institute expanded its existing cancer antibody development pact with three new targets provided by Brazilian antibody developer Recepta Biopharma SA. The partners will focus their R&D partnership on the generation of three antibodies targeting important cancer immune checkpoints. Under the terms of the agreement, 4-Antibody will use its high-throughput Retrocyte Display® technology platform to generate and produce fully human therapeutic antibody candidates. The Ludwig Institute will validate the new constructs and then, together with Recepta Biopharma, will take these antibody drugs into early clinical testing from 2015 in the US and Brazil.  

4-Antibody and Ludwig jointly will own the antibody drugs while Recepta Biopharma has baged exclusive commercial rights to Brazil in return for undisclosed licensing fees. 4-Antibody will take the lead securing commercialisation partners for the antibody drugs in territories outside Brazil on behalf of itself and Ludwig. Future returns from the collaboration outside of Brazil will be shared among the three parties.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/new-cancer-collaborations.html

New reportEU

25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.

M&AIreland

19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.

Drug DevelopmentGermany

18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.

FinanceFrance

14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.

AwardsFranceGermanySweden

12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.

ResearchEU

10.11.2014 EFPIA’s specialised group Vaccines Europe and the Innovative Medicines Initiative (IMI) have launched a €280m Call for proposals aimed to address the Ebola crisis.

Trade fairGermanyEU

07.11.2014 3,200 participants from 54 countries attended the 20th issue of BIO-Europe. The overall mood of the European biotech sector was modestly optimistic.

AcquisitionGermanyUKSweden

05.11.2014 German Definiens AG has a new owner: Astrazeneca’s biologics R&D arm Medimmune has taken over all the shares of the imaging specialist for US$150m.

AcquisitionSwedenDenmarkUK

04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.

FinancingSwedenNorway

31.10.2014 Another biotech is leaving the European market place in favour of a US IPO. Swedish Cortendo is now planning to go public in the US after raising €8.8m in bridge financing.

Events

All Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • FORMYCON10.43 EUR7.08%
  • EVOTEC3.27 EUR4.47%
  • MORPHOSYS78.71 EUR1.88%

FLOP

  • THERAMETRICS0.07 CHF-12.50%
  • 4SC0.89 EUR-5.32%
  • CYTOS0.28 CHF-3.45%

TOP

  • CYTOS0.28 CHF75.0%
  • EPIGENOMICS5.14 EUR45.6%
  • FORMYCON10.43 EUR32.9%

FLOP

  • THERAMETRICS0.07 CHF-12.5%
  • BIOFRONTERA2.54 EUR-12.4%
  • CO.DON2.50 EUR-9.1%

TOP

  • SANTHERA92.25 CHF2738.5%
  • CO.DON2.50 EUR150.0%
  • BB BIOTECH183.00 EUR63.4%

FLOP

  • CYTOS0.28 CHF-91.7%
  • 4SC0.89 EUR-49.1%
  • THERAMETRICS0.07 CHF-46.2%

No liability assumed, Date: 24.11.2014